Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...
Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned ...
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback